Clinical Trials for Other Solid Tumor

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial involves treatment-naïve patients with stage IV NSCLC, testing pembrolizumab alone or in combination with chemotherapy and investigational agents like vibostolimab, boserolimab, MK-4830, MK-0482, I-DXd, and HER3-DXd, which target immune checkpoints, PD-1, HER3, and cancer evasion mechanisms to enhance anti-tumor responses.

ClinicalTrials.gov ID: NCT04165070

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in adult patients with advanced or metastatic non-small cell lung cancer (NSCLC), including those experienced with checkpoint inhibitors, focusing on safety, pharmacokinetics, and efficacy measures.

ClinicalTrials.gov ID: NCT04995523

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the combination of atezolizumab, a PD-L1 inhibitor that reactivates anticancer immune responses, with pirfenidone in adult patients with stage 4 NSCLC lacking actionable mutations who have progressed after PD-1/PD-L1 inhibitor therapy, with or without prior chemotherapy. Eligible patients must have a performance status of ECOG 0-2 and adequate organ function, while exclusions apply to those with severe uncontrolled conditions or active auto-immune diseases.

ClinicalTrials.gov ID: NCT04467723

Transarterial Chemoembolization for the Treatment of Lung Cancer and Lung Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the use of transarterial chemoembolization (TACE) with mitomycin, Lipiodol, and Embospheres in adult patients with chemorefractory, unresectable, and unablatable non-small cell lung cancer or lung metastases predominantly in the chest.

ClinicalTrials.gov ID: NCT05672108

A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates SKB264, an antibody-drug conjugate targeting TROP2, in adult patients aged 18-75 with advanced solid tumors unresponsive to standard treatments, including specific interests like triple-negative breast and non-small cell lung cancers. The study aims to determine safety, efficacy, and recommended dosing of SKB264, focusing on cancers where TROP2 is prevalent.

ClinicalTrials.gov ID: NCT04152499

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the safety and preliminary anti-tumor activity of IDE397, a MAT2A inhibitor, in adult patients with MTAP-deleted advanced solid tumors, either as monotherapy or in combination with docetaxel, paclitaxel, or sacituzumab govitecan. Eligible patients must have advanced or metastatic solid tumors that have failed at least one prior treatment line.

ClinicalTrials.gov ID: NCT04794699

Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of WSD0922-FU

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the safety, tolerability, and anti-tumor activity of WSD0922-FU, an EGFR/EGFRvIII inhibitor, in patients with recurrent glioblastoma, anaplastic astrocytoma, and EGFR-mutant non-small cell lung cancer with CNS metastases. It involves dose-escalation to identify the maximum tolerated dose, focusing on patients with progressive disease and specific inclusion criteria.

ClinicalTrials.gov ID: NCT04197934

A Phase II Study of the Effects of Pembrolizumab on Quality of Life for Patients With Treatment-Naïve, Advanced or Metastatic NSCLC and Poor Performance Status

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates the effects of pembrolizumab on quality of life in treatment-naïve patients with advanced or metastatic NSCLC and poor performance status (ECOG 2 or 3) with a PD-L1 TPS ≥ 1%, who are unsuitable for standard treatments. Pembrolizumab, a PD-1 inhibitor, reactivates T-cells, aiming to improve outcomes and manage toxicity in this specific patient population.

ClinicalTrials.gov ID: NCT05589818

Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with stage IV or recurrent non-small cell lung cancer who have progressed despite prior anti-PD-1/PD-L1 therapy and platinum-based chemotherapy, comparing a novel combination of ramucirumab, a VEGFR-2 inhibitor, and pembrolizumab, a PD-1 inhibitor, against standard chemotherapy to evaluate overall survival benefits.

ClinicalTrials.gov ID: NCT05633602

Phase II Trial of Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets patients with Stage IV NSCLC who have high-risk thoracic lesions and lack targetable mutations such as EGFR or ALK, evaluating the efficacy of prophylactic palliative thoracic radiotherapy in combination with standard systemic therapies like chemotherapy or immunotherapy to prevent symptomatic progression in the thorax.

ClinicalTrials.gov ID: NCT06262321